How Has the Carcinoembryonic Antigen Market Evolved Historically and What is its Current Size?
The carcinoembryonic antigen market has seen considerable growth due to a variety of factors.
• The carcinoembryonic antigen market has expanded rapidly in recent years. It will grow from $1.22 billion in 2024 to $1.38 billion in 2025, at a compound annual growth rate (CAGR) of 13.7%.
Growth drivers include the increasing prevalence of cancer worldwide, the aging population, awareness campaigns, healthcare infrastructure improvements, and favorable reimbursement policies.
What is the Forecasted Market Size and CAGR for the Carcinoembryonic Antigen Market?
The carcinoembryonic antigen market is expected to maintain its strong growth trajectory in upcoming years.
• The carcinoembryonic antigen market is expected to grow rapidly, reaching $2.28 billion by 2029, with a CAGR of 13.4%.
This growth is driven by the focus on early detection, the expansion of cancer screening programs, patient demand for personalized medicine, and a preference for minimally invasive diagnostic procedures. Key trends include increased adoption of personalized medicine, advancements in diagnostic technology, AI and big data integration, partnerships, and regulatory approvals.
What Key Factors and Trends Are Driving The Growth Carcinoembryonic Antigen Market?
The rising incidence of cancer is expected to fuel the growth of the carcinoembryonic antigen market. Cancer's increasing prevalence is linked to lifestyle choices, environmental factors, genetics, and aging populations. Carcinoembryonic antigen (CEA) is a tumor marker used to monitor cancer progression and the effectiveness of treatment. The World Health Organization projected in February 2024 that cancer cases would rise to 35 million globally by 2050, a 77% increase from 2022. As such, the rising cancer incidence is driving the growth of the carcinoembryonic antigen market.
What Are The Market Segments In The Carcinoembryonic Antigen Market?
The carcinoembryonic antigen market covered in this report is segmented –
1) By Test Type: Molecular Tests, Serology Tests
2) By Gender: Male, Female
3) By Application: Gastrointestinal Cancer, Colorectal Cancer, Pancreatic Cancer, Breast Cancer, Lung Cancer, Thyroid Cancer, Ovarian Cancer, Other Applications
4) By End User: Hospitals, Diagnostic Centers, Cancer Centers, Research And Academic Institutes
Subsegments:
1) By Molecular Tests: Polymerase Chain Reaction (PCR), Reverse Transcription PCR (RT-PCR), Next-Generation Sequencing (NGS), Fluorescence In Situ Hybridization (FISH), Gene Expression Profiling
2) By Serology Tests: Enzyme-Linked Immunosorbent Assay (ELISA), Chemiluminescent Immunoassay (CLIA), Radioimmunoassay (RIA), Immunohistochemistry (IHC), Lateral Flow Assays
Pre-Book The Carcinoembryonic Antigen Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are Emerging Trends Reshaping The Dynamics Of The Carcinoembryonic Antigen Market?
Leading companies in the carcinoembryonic antigen market are enhancing their diagnostic offerings by developing tumor marker tests. These tests detect specific substances in the body that may indicate cancer. For instance, in July 2023, Roche Diagnostics, a Swiss company, launched the Elecsys HCV Duo test in India. This test simultaneously detects hepatitis C antigen and antibody from a single sample, improving early diagnosis and treatment for active infections, especially in high-risk populations.
Who Are the Key Players In The Carcinoembryonic Antigen Market?
Major companies operating in the carcinoembryonic antigen market are:
• F. Hoffmann-La Roche Ltd.
• Thermo Fisher Scientific Inc.
• Abbott Laboratories
• Merck KGaA
• Siemens Healthineers
• Laboratory Corporation of America Holdings
• Quest Diagnostics
• Agilient TechnologiesInc.
• Beckman Coulter Inc.
• bioMérieux SA
• Quidel Corporation
• Ortho Clinical Diagnostics
• Abcam plc
• RayBiotech Inc.
• Creative Diagnostics
• Lee Biosolutions Inc.
• Hytest Ltd.
• Prospec-Tany Technogene Ltd
• Boster Biological Technology
• Metropolis Healthcare
What Are The Regional Insights Into The Carcinoembryonic Antigen Market?
North America was the largest region in the carcinoembryonic antigen market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the carcinoembryonic antigen market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
